Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | WDR5 | P61964 | 5/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372705 | 0.81 | MCL1 (0.62) | CA12CA1CA2CA3CA4 | |
| SCHEMBL5203092 | 0.81 | PTGS1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26567167 | 0.79 | CA12 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11512510 | 0.79 | MCL1 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL32664450 | 0.79 | GAA (0.48) | HSD17B2TSHRFTOMEN1LMNA | |
| SCHEMBL11512517 | 0.79 | MCL1 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL10868958 | 0.79 | GAA (0.48) | HSD17B2TSHRFTOMEN1LMNA | |
| SCHEMBL3471628 | 0.78 | POLB (0.61) | P2RX1WDR5CA1CA2ACLY | |
| SCHEMBL25341310 | 0.78 | WDR5 (0.56) | WDR5ACLYMAPT | |
| SCHEMBL6130536 | 0.78 | CA12 (0.50) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058932-A1 | Novel piperazine derivatives | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6649611-B2 | Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1268455-A2 | PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072728-A9 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PROD INC (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020107255-A1 | Novel piperazine derivatives | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2001072728-A2 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058932-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | P2RX1 955/4885WDR5 1265/4885CA12 4590/4885 |
| US-20020107255-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | P2RX1 955/4885WDR5 1265/4885CA12 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.